Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR. Kapoor S, et al. Among authors: baer mr. Clin Cancer Res. 2018 Jan 1;24(1):234-247. doi: 10.1158/1078-0432.CCR-17-1629. Epub 2017 Oct 26. Clin Cancer Res. 2018. PMID: 29074603 Free PMC article.
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.
Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrózek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD. Caligiuri MA, et al. Among authors: baer mr. Cancer Res. 1998 Jan 1;58(1):55-9. Cancer Res. 1998. PMID: 9426057
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA. Lee EJ, et al. J Clin Oncol. 1999 Sep;17(9):2831-9. doi: 10.1200/JCO.1999.17.9.2831. J Clin Oncol. 1999. PMID: 10561359 Clinical Trial.
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA. Farag SS, et al. Clin Cancer Res. 2002 Sep;8(9):2812-9. Clin Cancer Res. 2002. PMID: 12231521 Clinical Trial.
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. Marcucci G, et al. Among authors: baer mr. J Clin Oncol. 2005 Dec 20;23(36):9234-42. doi: 10.1200/JCO.2005.03.6137. Epub 2005 Nov 7. J Clin Oncol. 2005. PMID: 16275934
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.
Wetzler M, Brady MT, Tracy E, Li ZR, Donohue KA, O'Loughlin KL, Cheng Y, Mortazavi A, McDonald AA, Kunapuli P, Wallace PK, Baer MR, Cowell JK, Baumann H. Wetzler M, et al. Among authors: baer mr. Clin Cancer Res. 2006 Nov 15;12(22):6817-25. doi: 10.1158/1078-0432.CCR-06-1354. Clin Cancer Res. 2006. PMID: 17121903 Free PMC article.
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Baer MR, et al. J Clin Oncol. 2008 Oct 20;26(30):4934-9. doi: 10.1200/JCO.2008.17.0472. Epub 2008 Jun 30. J Clin Oncol. 2008. PMID: 18591543 Free PMC article. Clinical Trial.
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S. Badros A, et al. Among authors: baer mr. Clin Cancer Res. 2009 Aug 15;15(16):5250-7. doi: 10.1158/1078-0432.CCR-08-2850. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671864 Free PMC article. Clinical Trial.
345 results